Platform - C2i Genomics

Overview

C2intelligence is making real-time cancer interception available worldwide. We provide unprecedented acuity in cancer detection and monitoring by combining whole genome sequencing (WGS) with a proprietary AI-based tumor enrichment method that recognizes patient-specific cancer patterns.

Reduce Operational Complexity With a Standardized Workflow.

Real-Time Cancer Detection
Results detecting even the smallest residual cancer burden from stage 1 or 2 within 48 hours of data being uploaded to the cloud.

Reduced Operational Burden
Automated, standardized blood test workflow leverages your current sequencer without the need for creating a patient-specific assay.

Ultra-Sensitive and Accurate
Whole-genome patient-specific mutation features (including complex signatures like SNV and CNV) capture cancer dynamics to provide actionable insights. Validated with over 1,000 samples.

Accessible Locally
Our cloud-based Software-as-a-Service platform is simple to implement and scale, allowing you to rapidly offer cutting-edge whole genome sequencing applications.

Cloud-based platform

Our SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world.

Utilizing our platform, our technology is accessible anywhere in the world, bringing high precision personalized cancer monitoring to a growing number of locations on the map.

12 WORLDWIDE SITES
6 ACTIVE STUDIES
1,000 SAMPLES PROCESSED

Incorporating C2intelligence Into Your Existing Workflow Is Simple. Comprehensive on-site validation process makes a seamless 2-3 month deployment possible without disrupting your existing processes.

Deploy globally with our cloud-based network
Works with off-the-shelf chemistries
Completely integrated IT
Cloud-based data storage and analysis

Our global lab partners

Key Advantages

Genomic Cloud Platform

Our cloud-based technology can be deployed globally at scale to provide actionable insights into the progression of any patient’s cancer as rapidly as in one week, enabling informed and timely treatment decisions.